BR112020015068A2 - Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano - Google Patents
Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano Download PDFInfo
- Publication number
- BR112020015068A2 BR112020015068A2 BR112020015068-1A BR112020015068A BR112020015068A2 BR 112020015068 A2 BR112020015068 A2 BR 112020015068A2 BR 112020015068 A BR112020015068 A BR 112020015068A BR 112020015068 A2 BR112020015068 A2 BR 112020015068A2
- Authority
- BR
- Brazil
- Prior art keywords
- htp
- carbidopa
- formulation
- fact
- low dose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 39
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims abstract description 189
- 229960004205 carbidopa Drugs 0.000 claims abstract description 123
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 119
- 238000009472 formulation Methods 0.000 claims abstract description 47
- 238000011260 co-administration Methods 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 34
- 229940076279 serotonin Drugs 0.000 claims description 33
- 241000282414 Homo sapiens Species 0.000 claims description 24
- 239000002552 dosage form Substances 0.000 claims description 23
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 9
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 9
- 206010010144 Completed suicide Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 6
- 238000009097 single-agent therapy Methods 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 4
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 206010003805 Autism Diseases 0.000 claims description 3
- 208000020706 Autistic disease Diseases 0.000 claims description 3
- 206010013954 Dysphoria Diseases 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims description 3
- 230000016571 aggressive behavior Effects 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 208000030963 borderline personality disease Diseases 0.000 claims description 3
- USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 3
- 229960005217 dapoxetine Drugs 0.000 claims description 3
- 229960004341 escitalopram Drugs 0.000 claims description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 3
- 229960002464 fluoxetine Drugs 0.000 claims description 3
- 229960004038 fluvoxamine Drugs 0.000 claims description 3
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 3
- 230000005032 impulse control Effects 0.000 claims description 3
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims description 3
- 229950002473 indalpine Drugs 0.000 claims description 3
- 239000000543 intermediate Substances 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229960002073 sertraline Drugs 0.000 claims description 3
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims description 3
- 229960003740 vilazodone Drugs 0.000 claims description 3
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 claims description 3
- YQNWZWMKLDQSAC-UHFFFAOYSA-N vortioxetine Chemical compound CC1=CC(C)=CC=C1SC1=CC=CC=C1N1CCNCC1 YQNWZWMKLDQSAC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002263 vortioxetine Drugs 0.000 claims description 3
- 229960002791 zimeldine Drugs 0.000 claims description 3
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- 201000009916 Postpartum depression Diseases 0.000 claims description 2
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
- 229960001653 citalopram Drugs 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 2
- 229940041672 oral gel Drugs 0.000 claims description 2
- 208000007656 osteochondritis dissecans Diseases 0.000 claims description 2
- 208000019906 panic disease Diseases 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 239000006215 rectal suppository Substances 0.000 claims description 2
- 229940100618 rectal suppository Drugs 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 239000003174 triple reuptake inhibitor Substances 0.000 claims description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000037058 blood plasma level Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 abstract description 170
- 229940000681 5-hydroxytryptophan Drugs 0.000 abstract description 168
- 210000004556 brain Anatomy 0.000 description 35
- 241000699670 Mus sp. Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 19
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 19
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 11
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 11
- 229960004502 levodopa Drugs 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 230000002411 adverse Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 7
- 229960000911 benserazide Drugs 0.000 description 7
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 6
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000001839 systemic circulation Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000011278 co-treatment Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 150000004803 5-hydroxytryptophans Chemical class 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 3
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000010149 post-hoc-test Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 2
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
- 208000030990 Impulse-control disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- -1 amphetamines Chemical compound 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- IJAGKEKOJGWANE-KCBWXHRDSA-N (3r,4r,5r)-5-[(2s,3r)-4-[(e)-2-carboxyethenyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carbonyl]oxy-3,4-dihydroxycyclohexene-1-carboxylic acid Chemical compound O[C@@H]1[C@H](O)C=C(C(O)=O)C[C@H]1OC(=O)[C@@H]1C(C(\C=C\C(O)=O)=CC=C2O)=C2O[C@@H]1C1=CC=C(O)C(O)=C1 IJAGKEKOJGWANE-KCBWXHRDSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000219726 Griffonia simplicifolia Species 0.000 description 1
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009415 formwork Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 230000009546 growth abnormality Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623073P | 2018-01-29 | 2018-01-29 | |
| US62/623,073 | 2018-01-29 | ||
| US201862743816P | 2018-10-10 | 2018-10-10 | |
| US62/743,816 | 2018-10-10 | ||
| PCT/US2019/015391 WO2019148087A1 (en) | 2018-01-29 | 2019-01-28 | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020015068A2 true BR112020015068A2 (pt) | 2021-01-05 |
Family
ID=67395723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020015068-1A BR112020015068A2 (pt) | 2018-01-29 | 2019-01-28 | Composições e métodos de melhoramento de biodisponibilidade de 5-hidroxitriptofano |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11337963B2 (https=) |
| EP (1) | EP3746058B1 (https=) |
| JP (2) | JP7758320B2 (https=) |
| KR (2) | KR20200116110A (https=) |
| CN (1) | CN111902137A (https=) |
| AU (1) | AU2019211458B2 (https=) |
| BR (1) | BR112020015068A2 (https=) |
| ES (1) | ES2948788T3 (https=) |
| IL (1) | IL276059B2 (https=) |
| MX (1) | MX2020007760A (https=) |
| MY (1) | MY209656A (https=) |
| RU (1) | RU2020125170A (https=) |
| SG (1) | SG11202007178VA (https=) |
| WO (1) | WO2019148087A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12409163B2 (en) * | 2021-07-30 | 2025-09-09 | Evecxia Therapeutics, Inc. | Method of enhancing 5-hydroxytryptophan (5-HTP) exposure |
| WO2023009841A1 (en) * | 2021-07-30 | 2023-02-02 | Evecxia Therapeutics, Inc. | 5-hydroxytryptophan gastroretentive dosage forms |
| US11779567B2 (en) | 2021-10-14 | 2023-10-10 | Evecxia Therapeutics, Inc. | Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes |
| DE102022103658A1 (de) * | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
| WO2024148354A1 (en) | 2023-01-06 | 2024-07-11 | Evecxia Therapeutics, Inc. | A method of enhancing 5-hydroxytryptophan (5-htp) exposure |
| CN119074695A (zh) * | 2024-08-29 | 2024-12-06 | 江南大学 | 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4658038A (en) | 1982-10-07 | 1987-04-14 | Research Foundation For Mental Hygiene, Inc. | N-acylated 5-hydroxytryptophan amide derivatives |
| FR2654931B1 (fr) * | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| US6207699B1 (en) | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| AU2003293423A1 (en) | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| EP1746985A4 (en) * | 2004-05-21 | 2010-08-11 | Univ Duke | METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS |
| US20070213370A1 (en) | 2005-11-18 | 2007-09-13 | H. Lundbeck A/S | 5-HTP Combination Therapy |
| US8969400B2 (en) | 2007-10-01 | 2015-03-03 | Duke University | Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound |
| JP2012500221A (ja) | 2008-08-15 | 2012-01-05 | ディポメド，インコーポレイティド | Ｃｎｓ障害の処理及び予防のための胃保持性医薬組成物 |
| RU2012133467A (ru) * | 2010-02-05 | 2014-02-10 | Фосфейдженикс Лимитед | Композиция носителя |
| EP2629615B1 (en) * | 2010-10-22 | 2018-10-10 | Duke University | Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies |
| CN103554005A (zh) | 2013-11-22 | 2014-02-05 | 长沙理工大学 | 一种左旋5-羟基色氨酸的简便合成新方法 |
-
2019
- 2019-01-28 BR BR112020015068-1A patent/BR112020015068A2/pt unknown
- 2019-01-28 EP EP19743636.3A patent/EP3746058B1/en active Active
- 2019-01-28 MX MX2020007760A patent/MX2020007760A/es unknown
- 2019-01-28 MY MYPI2020003883A patent/MY209656A/en unknown
- 2019-01-28 RU RU2020125170A patent/RU2020125170A/ru unknown
- 2019-01-28 SG SG11202007178VA patent/SG11202007178VA/en unknown
- 2019-01-28 US US15/733,423 patent/US11337963B2/en active Active
- 2019-01-28 AU AU2019211458A patent/AU2019211458B2/en active Active
- 2019-01-28 CN CN201980021717.5A patent/CN111902137A/zh active Pending
- 2019-01-28 KR KR1020207024221A patent/KR20200116110A/ko not_active Ceased
- 2019-01-28 WO PCT/US2019/015391 patent/WO2019148087A1/en not_active Ceased
- 2019-01-28 KR KR1020257004583A patent/KR20250025043A/ko active Pending
- 2019-01-28 ES ES19743636T patent/ES2948788T3/es active Active
- 2019-01-28 JP JP2020541352A patent/JP7758320B2/ja active Active
- 2019-01-28 IL IL276059A patent/IL276059B2/en unknown
-
2023
- 2023-07-21 JP JP2023119314A patent/JP2023153871A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL276059B2 (en) | 2024-08-01 |
| EP3746058B1 (en) | 2023-06-07 |
| EP3746058A4 (en) | 2021-12-22 |
| JP7758320B2 (ja) | 2025-10-22 |
| AU2019211458B2 (en) | 2024-08-29 |
| MX2020007760A (es) | 2020-10-28 |
| CN111902137A (zh) | 2020-11-06 |
| AU2019211458A1 (en) | 2020-08-06 |
| EP3746058C0 (en) | 2023-06-07 |
| KR20200116110A (ko) | 2020-10-08 |
| JP2023153871A (ja) | 2023-10-18 |
| ES2948788T3 (es) | 2023-09-19 |
| KR20250025043A (ko) | 2025-02-20 |
| US11337963B2 (en) | 2022-05-24 |
| RU2020125170A (ru) | 2022-02-28 |
| WO2019148087A1 (en) | 2019-08-01 |
| EP3746058A1 (en) | 2020-12-09 |
| JP2021511365A (ja) | 2021-05-06 |
| IL276059A (en) | 2020-08-31 |
| US20210346345A1 (en) | 2021-11-11 |
| IL276059B1 (en) | 2024-04-01 |
| CA3089068A1 (en) | 2019-08-01 |
| MY209656A (en) | 2025-07-29 |
| SG11202007178VA (en) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2948788T3 (es) | Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano | |
| Harkin et al. | Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test | |
| Pilc et al. | Glutamate-based antidepressants: preclinical psychopharmacology | |
| Serafini et al. | Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression | |
| Mathews et al. | Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date | |
| Vázquez-Palacios et al. | Antidepressant effects of nicotine and fluoxetine in an animal model of depression induced by neonatal treatment with clomipramine | |
| Cunha et al. | The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test | |
| Zurowski et al. | Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism | |
| Rivara et al. | Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012–2014) | |
| Masana et al. | Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies | |
| Poleszak et al. | A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice | |
| US12390470B2 (en) | 1-methylxanthine-based bioactive composition and method of use thereof | |
| Chen et al. | Fluoroethylnormemantine, a novel NMDA receptor antagonist, for the prevention and treatment of stress-induced maladaptive behavior | |
| BR112020004622A2 (pt) | pridopidina para tratamento de discinesias induzidas por droga | |
| Yu et al. | Serotonergically dependent antihyperalgesic and antiallodynic effects of isoliquiritin in a mouse model of neuropathic pain | |
| KR20060032598A (ko) | 세로토닌 재흡수 억제제 및 아고멜라틴의 조합 | |
| Sanberg et al. | Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond | |
| Overall | Behavioral pharmacotherapeutics | |
| Karcz-Kubicha et al. | GlycineB antagonists and partial agonists in rodent models of Parkinson’s disease—comparison with uncompetitive N-methyl-D-aspartate receptor antagonist | |
| CA3089068C (en) | Low-dose carbidopa for enhancing 5-hydroxytryptophan bioavailability | |
| Yasar et al. | Metabolic Transformation Plays a Primary Role in the Psychostimulant-Like Discriminative-Stimulus Effects of Selegiline [(R)-(–)-Deprenyl] | |
| Carnevale et al. | Influence of Griffonia simplicifolia on male sexual behavior in rats: behavioral and neurochemical study | |
| Sela et al. | Serotonin-1A receptors in the dorsal periaqueductal gray matter mediate the panicolytic-like effect of pindolol and paroxetine combination in the elevated T-maze | |
| ZA200509356B (en) | Gaboxadol for treating depression and other affective disorders | |
| TW202024040A (zh) | 胺基甲酸酯化合物及包括該化合物之組合於預防、緩解或治療急性壓力症或創傷後壓力症之用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |